Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta's President and Chief Executive Officer, will make a formal presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time. The presentation will contain a business overview and an update on Enanta's research and development programs. A separate question and answer session with investors will follow the presentation and will be webcast.

Webcast Information
Enanta's presentation will take place on January 13, 2020 beginning at 2:30 p.m. Pacific Time. A live webcast of the presentation, as well as the question and answer session that follows the presentation, will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcasts will be and will be archived for approximately 30 days.

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Enanta's research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its leading treatment for chronic hepatitis C virus (HCV) infection sold under the tradenames MAVYRET® (U.S.) and MAVIRETtm (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 09:48
Roborock, a global leader in ultra-intelligent home robotics engineered to simplify daily life, today announced its financial results for the full year ending December 31, 2023....

at 09:45
Blueground, the largest global operator of furnished, flexible rentals for 30+ day stays, today announced that it has secured $45 million in Series D funding. The raise includes investments from new investor Susquehanna Private Equity Investments,...

at 09:45
GPT Protocol, (MEXC: GPT) (UNI: GPT), a decentralized platform at the intersection of AI and blockchain on a mission to democratize AI development through its censorship-resistant applications, is pleased to announce its upcoming participation in the...

at 09:45
Julien's Auctions today announced a series of additions to its senior...

at 09:44
Following the success of its record-breaking 2023 event, HK Web3 Festival is returning for its second edition from 6 to 9, April at Hall3FG, Hong Kong Convention and Exhibition Centre. Hosted by Wanxiang Blockchain Labs and HashKey Group, the...

at 09:35
Netradyne, an industry-leading SaaS provider of artificial intelligence (AI), edge computing, and full-service telematics provider focused on safety and driver coaching for commercial fleets, today announced the expanded rollout of new patented...



News published on and distributed by: